Abstract 1576P
Background
In Italy, progress in lung cancer mortality in men is not paralleled by similar trends in women, though exposure to tobacco smoking is well known to be the key driver of lung cancer incidence and mortality. This study aimed to compare recent trends in lung cancer mortality rates in Italian men and women.
Methods
Mortality data for 2003-2019 were retrieved from death certificates compiled by the Italian National Institute for Statistics. These data were used to compute, separately in men and women, age-standardized mortality rates (/105/year) for lung cancer (ICD-10: C33-C34.9). Furthermore, we estimated the absolute number of prevented lung cancer deaths in 2007-2019 in Italy, as the difference between the observed and expected (based on the 2003-2006 mortality rates) number of lung cancer deaths. Data on the prevalence of tobacco smoking in men and women were collected from national surveys.
Results
In Italian men, the use of tobacco smoking strongly declined from 60% in the 1960s to 27.7% in 2021, whereas it tended to increase in women – particularly in the two last decades from 16.6% in 2004 to 20.7% in 2021. In men, a decline from 2007 to 2019 in lung cancer mortality rates was documented in all geographic areas (e.g., from 121.2/105 to 92.6/105 in northern Italy; and from 98.5/105 to 91.4/105 in southern Italy). Conversely, upward trends were registered for women: from 30.3/105 to 33.8/105 in the North; and from 16.3/105 to 20.3/105 in the South. From 2007 to 2019, there was an 18.7% reduction in the expected number of lung cancer deaths in men (-73.397) and an increase of 16.0% in expected deaths in women (+16.036).
Conclusions
Study findings strengthen the persistent need for tailoring interventions to reduce smoking among females to invert lung cancer mortality trends in Italian women.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Italian Ministry of Health, Ricerca Corrente IRCCS CRO, Aviano.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1584P - Association of travel burden (TB) with colorectal cancer (CRC) outcomes in resource-limited settings (RLS)
Presenter: Saquib Banday
Session: Poster session 10
1585P - Performance status restrictions in clinical trials leading to US food and drug administration (FDA) drug approval: A cross-sectional study of a decade (2014-2023)
Presenter: Giovanni Maria Iannantuono
Session: Poster session 10
1586P - Current status of breast cancer: A comparative analysis between developed and developing countries
Presenter: Ana Isabel Martin Quesada
Session: Poster session 10
1587P - As seen through Hollywood’s lens: Cancer in movies, 2010-2020
Presenter: David Benjamin
Session: Poster session 10
1588P - Interventions to improve Herpes Zoster (HZ) vaccination rate among cancer outpatients receiving systemic treatments: A single-center real-world experience
Presenter: Sara Di Bella
Session: Poster session 10
1589P - Ramping up phase I trial recruitment: Defining potential barriers and disparities
Presenter: Burak Aktas
Session: Poster session 10
1590P - Prevalence and impact on survival of presentation to the emergency room of cancer patients: A retrospective study on real-life data
Presenter: Sonia Priou
Session: Poster session 10
1591P - Development and economic trends in new anticancer therapies licensed in the UK from 2020 to 2024
Presenter: Geetin Majhail
Session: Poster session 10
1592P - Awareness and interest of oncology professionals in sex and gender differences in cancer risk and outcome: Analysis of an ESMO Gender Medicine Task Force survey
Presenter: Berna C. Özdemir
Session: Poster session 10
1593P - Factors associated with multiple general practitioner consultations before cancer diagnosis in adolescents and young adults: A cohort study in Australia
Presenter: Jeremy Lewin
Session: Poster session 10